In vitro evaluation of liposomal cyclosporine

Kiumars Vadiei, Gabriel Lopez-Berestein, Roman Perez-Soler, David R. Luke

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The commercially available intravenous formulation of cyclosporine (CSA) is associated with acute hemodynamic changes, resulting in significant renal dysfunction. The present study investigated the properties of two liposomal CSA formulations: dimyristoylphosphatidylcholine (DMPC): stearylamine 7:1 (A) and DMPC: dimyristoylphosphatidylglycerol (DMPG) 4:1 molar ratio (B) developed as an alternative for the i.v. CSA. The optimal drug: lipid weight ratio was 1:20 for both formulations. The liposomal suspensions were obtained by rehydrating the lyophilized powder containing CSA and the lipids with saline. CSA entrapment was 90-95% for both formulations. The encapsulation efficiency of the lyophilized powder stored at 2-5°C was 95% at 24 h and not significantly different with either formulation. The encapsulation efficiency of liposomal formulations A and B in saline was 99 ± 1 and 50 ± 1%, respectively, after 5 days. In 50% serum, the encapsulation efficiency measured as percentage drug remaining entrapped at different time points was 90 ± 3 and 53 ± 4% for A and B, respectively, at 24 h. In vitro activity of both liposomal formulations demonstrated greater potency compared to the commercially available CSA i.v. formulation (A, 69.3 ± 14.8%; B, 50.8 ± 11.5%; i.v., 27.4 ± 20.6% inhibition of T-lymphocyte proliferation; p < 0.05 at 10-3 mM). The present study shows that liposomes can be used as a drug delivery system for CSA and result in an enhanced in vitro immunosuppressive potency compared with the i.v. formulation.

Original languageEnglish (US)
Pages (from-to)133-138
Number of pages6
JournalInternational Journal of Pharmaceutics
Volume57
Issue number2
DOIs
StatePublished - Dec 22 1989
Externally publishedYes

Fingerprint

Dimyristoylphosphatidylcholine
Powders
Cyclosporine
Lipids
Drug Delivery Systems
Immunosuppressive Agents
Liposomes
Pharmaceutical Preparations
Suspensions
Hemodynamics
T-Lymphocytes
Kidney
Weights and Measures
Serum
In Vitro Techniques
stearylamine
dimyristoylphosphatidylglycerol

Keywords

  • Cyclosporine
  • Intravenous formulation
  • Liposomes
  • T-lymphocyte proliferation

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

In vitro evaluation of liposomal cyclosporine. / Vadiei, Kiumars; Lopez-Berestein, Gabriel; Perez-Soler, Roman; Luke, David R.

In: International Journal of Pharmaceutics, Vol. 57, No. 2, 22.12.1989, p. 133-138.

Research output: Contribution to journalArticle

Vadiei, Kiumars ; Lopez-Berestein, Gabriel ; Perez-Soler, Roman ; Luke, David R. / In vitro evaluation of liposomal cyclosporine. In: International Journal of Pharmaceutics. 1989 ; Vol. 57, No. 2. pp. 133-138.
@article{461c00b824b549599e317d522925d0c8,
title = "In vitro evaluation of liposomal cyclosporine",
abstract = "The commercially available intravenous formulation of cyclosporine (CSA) is associated with acute hemodynamic changes, resulting in significant renal dysfunction. The present study investigated the properties of two liposomal CSA formulations: dimyristoylphosphatidylcholine (DMPC): stearylamine 7:1 (A) and DMPC: dimyristoylphosphatidylglycerol (DMPG) 4:1 molar ratio (B) developed as an alternative for the i.v. CSA. The optimal drug: lipid weight ratio was 1:20 for both formulations. The liposomal suspensions were obtained by rehydrating the lyophilized powder containing CSA and the lipids with saline. CSA entrapment was 90-95{\%} for both formulations. The encapsulation efficiency of the lyophilized powder stored at 2-5°C was 95{\%} at 24 h and not significantly different with either formulation. The encapsulation efficiency of liposomal formulations A and B in saline was 99 ± 1 and 50 ± 1{\%}, respectively, after 5 days. In 50{\%} serum, the encapsulation efficiency measured as percentage drug remaining entrapped at different time points was 90 ± 3 and 53 ± 4{\%} for A and B, respectively, at 24 h. In vitro activity of both liposomal formulations demonstrated greater potency compared to the commercially available CSA i.v. formulation (A, 69.3 ± 14.8{\%}; B, 50.8 ± 11.5{\%}; i.v., 27.4 ± 20.6{\%} inhibition of T-lymphocyte proliferation; p < 0.05 at 10-3 mM). The present study shows that liposomes can be used as a drug delivery system for CSA and result in an enhanced in vitro immunosuppressive potency compared with the i.v. formulation.",
keywords = "Cyclosporine, Intravenous formulation, Liposomes, T-lymphocyte proliferation",
author = "Kiumars Vadiei and Gabriel Lopez-Berestein and Roman Perez-Soler and Luke, {David R.}",
year = "1989",
month = "12",
day = "22",
doi = "10.1016/0378-5173(89)90301-3",
language = "English (US)",
volume = "57",
pages = "133--138",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - In vitro evaluation of liposomal cyclosporine

AU - Vadiei, Kiumars

AU - Lopez-Berestein, Gabriel

AU - Perez-Soler, Roman

AU - Luke, David R.

PY - 1989/12/22

Y1 - 1989/12/22

N2 - The commercially available intravenous formulation of cyclosporine (CSA) is associated with acute hemodynamic changes, resulting in significant renal dysfunction. The present study investigated the properties of two liposomal CSA formulations: dimyristoylphosphatidylcholine (DMPC): stearylamine 7:1 (A) and DMPC: dimyristoylphosphatidylglycerol (DMPG) 4:1 molar ratio (B) developed as an alternative for the i.v. CSA. The optimal drug: lipid weight ratio was 1:20 for both formulations. The liposomal suspensions were obtained by rehydrating the lyophilized powder containing CSA and the lipids with saline. CSA entrapment was 90-95% for both formulations. The encapsulation efficiency of the lyophilized powder stored at 2-5°C was 95% at 24 h and not significantly different with either formulation. The encapsulation efficiency of liposomal formulations A and B in saline was 99 ± 1 and 50 ± 1%, respectively, after 5 days. In 50% serum, the encapsulation efficiency measured as percentage drug remaining entrapped at different time points was 90 ± 3 and 53 ± 4% for A and B, respectively, at 24 h. In vitro activity of both liposomal formulations demonstrated greater potency compared to the commercially available CSA i.v. formulation (A, 69.3 ± 14.8%; B, 50.8 ± 11.5%; i.v., 27.4 ± 20.6% inhibition of T-lymphocyte proliferation; p < 0.05 at 10-3 mM). The present study shows that liposomes can be used as a drug delivery system for CSA and result in an enhanced in vitro immunosuppressive potency compared with the i.v. formulation.

AB - The commercially available intravenous formulation of cyclosporine (CSA) is associated with acute hemodynamic changes, resulting in significant renal dysfunction. The present study investigated the properties of two liposomal CSA formulations: dimyristoylphosphatidylcholine (DMPC): stearylamine 7:1 (A) and DMPC: dimyristoylphosphatidylglycerol (DMPG) 4:1 molar ratio (B) developed as an alternative for the i.v. CSA. The optimal drug: lipid weight ratio was 1:20 for both formulations. The liposomal suspensions were obtained by rehydrating the lyophilized powder containing CSA and the lipids with saline. CSA entrapment was 90-95% for both formulations. The encapsulation efficiency of the lyophilized powder stored at 2-5°C was 95% at 24 h and not significantly different with either formulation. The encapsulation efficiency of liposomal formulations A and B in saline was 99 ± 1 and 50 ± 1%, respectively, after 5 days. In 50% serum, the encapsulation efficiency measured as percentage drug remaining entrapped at different time points was 90 ± 3 and 53 ± 4% for A and B, respectively, at 24 h. In vitro activity of both liposomal formulations demonstrated greater potency compared to the commercially available CSA i.v. formulation (A, 69.3 ± 14.8%; B, 50.8 ± 11.5%; i.v., 27.4 ± 20.6% inhibition of T-lymphocyte proliferation; p < 0.05 at 10-3 mM). The present study shows that liposomes can be used as a drug delivery system for CSA and result in an enhanced in vitro immunosuppressive potency compared with the i.v. formulation.

KW - Cyclosporine

KW - Intravenous formulation

KW - Liposomes

KW - T-lymphocyte proliferation

UR - http://www.scopus.com/inward/record.url?scp=0024822346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024822346&partnerID=8YFLogxK

U2 - 10.1016/0378-5173(89)90301-3

DO - 10.1016/0378-5173(89)90301-3

M3 - Article

AN - SCOPUS:0024822346

VL - 57

SP - 133

EP - 138

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 2

ER -